WASHINGTON--(BUSINESS WIRE)--Idera Pharmaceuticals (AMEX: IDP) today presented data for a novel class of compounds which act as antagonists of specific Toll-Like Receptors (TLR). In preclinical studies, these antagonists have been shown to block immune activation through TLR7, 8, and 9, as evaluated by use of agonists specific to these receptors. The antagonists have been shown to be specific for TLR7, 8, and 9, as immune activation by agonists to other TLRs was not blocked. The oral presentation entitled “DNA-based antagonists for TLR7, 8, and 9: Potential applications in autoimmune disorders” (Abstract # BRC2) was made at the Innate Immune Receptors and Responses session during the American College of Rheumatology Basic Research Conference being held in Washington, D.C., today beginning at 10:35 a.m. ET.